Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ON THE SELECTION OF DRUGS DOSAGE REGIMEN

https://doi.org/10.20996/1819-6446-2015-11-1-92-95

Full Text:

Abstract

A complex system of hemostasis regulation, insufficient data on drugs pharmacokinetics, multiple factors effecting treatment, including patient’s adherence to therapy, that can lead to the need for the dosage regimen specification are presented.

About the Author

E. N. Bochanova
Krasnoyarsk State Medical University named after V.F. Voino-Yasenetsky
Russian Federation
Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia


References

1. Belousov YB, Kukes VG, Lepahin VK, Petrov VI, eds. Clinical pharmacology. National guidance. Moscow: GEOTAR-Media; 2014. Russian (Белоусов Ю.Б., Кукес В.Г., Лепахин В.К., Петров В.И., редакторы. Клиническая фармакология. Национальное руководство. М.: Гэотар-Медиа; 2014).

2. Clemens A, Haertter S, Friedman J, et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 2012;28:195-201

3. Belousov YB, Leonova MV, eds. Fundamentals of clinical pharmacology and rational pharmacotherapy: A Guide for practitioners. Moscow: Litterra; 2002. Russian (Белоусов Ю.Б., Леонова М.В., редакторы. Основы клинической фармакологии и рациональной фармакотерапии: Руководство для практикующих врачей. М.: ЛитТерра; 2002)

4. Comté L1, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007;34(4):549-58.

5. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74.

6. Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9.

7. Reshet'ko OV, Lutsevich KA, Ardentova NN, Lutsevich TS. Lack of adherence to treatment as a problem of rational pharmacotherapy. Klinicheskaya Farmakologiya i Terapiya 2010; 19 (2): 75-80. Russian (Решетько О.В., Луцевич К.А., Ардентова Н.Н, Луцевич Т.С. Отсутствие приверженности к лечению как проблема рациональной фармакотерапии. Клиническая Фармакология и Терапия 2010; 19 (2): 75-80)

8. Eriksson B Dahl OE, Büller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3(1):103-11.

9. Sairaku A, Yoshida Y, Ando M, A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation. Clin Drug Investig 2013;33(11):847-53.


For citation:


Bochanova E.N. ON THE SELECTION OF DRUGS DOSAGE REGIMEN. Rational Pharmacotherapy in Cardiology. 2015;11(1):92-95. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-1-92-95

Views: 283


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)